Lomotil and Obstruction - a phase IV clinical study of FDA data

Summary:

Obstruction is reported as a side effect among people who take Lomotil (atropine sulfate; diphenoxylate hydrochloride), especially for people who are female, 60+ old, also take Imodium, and have Short-bowel syndrome.

The phase IV clinical study analyzes which people have Obstruction when taking Lomotil. It is created by eHealthMe based on reports of 18,891 people who have side effects when taking Lomotil from the FDA, and is updated regularly.

What is Lomotil?

Lomotil has active ingredients of atropine sulfate; diphenoxylate hydrochloride. It is often used in diarrhea. eHealthMe is studying from 19,184 Lomotil users. Check the latest studies of Lomotil.

What is Obstruction?

Obstruction is found to be associated with 469 drugs and 647 conditions by eHealthMe. Check the latest studies of Obstruction.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

18,891 people reported to have side effects when taking Lomotil.
Among them, 32 people (0.17%) have Obstruction.

Among these 32 people:

What is the gender of people who have Obstruction when taking Lomotil? *

female: 70.97 %
male: 29.03 %

What is the age of people who have Obstruction when taking Lomotil? *

What are other drugs people take besides Lomotil? *

What are other side effects people have besides Obstruction? *

Nausea And Vomiting: 16 people, 50.00%
Pain: 13 people, 40.62%
Weakness: 11 people, 34.38%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 10 people, 31.25%
Colitis (inflammation of colon): 10 people, 31.25%
Nausea (feeling of having an urge to vomit): 10 people, 31.25%
Infection: 9 people, 28.12%
Dehydration (dryness resulting from the removal of water): 9 people, 28.12%
Swelling: 8 people, 25.00%
Malaise (a feeling of general discomfort or uneasiness): 8 people, 25.00%

What are the existing conditions these people have? *

Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 13 people, 40.62%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 9 people, 28.12%
Malabsorption (a state arising from abnormality in absorption of food nutrients across the gastrointestinal (gi) tract): 6 people, 18.75%
Nausea (feeling of having an urge to vomit): 5 people, 15.62%
Abnormal Faeces (abnormal stool): 3 people, 9.38%
Carcinoid Tumor: 3 people, 9.38%
Nausea And Vomiting: 2 people, 6.25%
Carcinoid Tumor Of The Small Bowel: 2 people, 6.25%
Abdominal Discomfort: 2 people, 6.25%
Neoplasm Malignant (cancer tumour): 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Lomotil and have Obstruction?

- Check whether Obstruction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lomotil:

Lomotil (19,184 reports)

Obstruction treatments and more:

Obstruction (4,654 reports)

How severe was Obstruction and when was it recovered:

Obstruction in Lomotil

Expand to all the drugs that have ingredients of atropine sulfate; diphenoxylate hydrochloride:

Obstruction and drugs with ingredients of atropine sulfate; diphenoxylate hydrochloride

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lomotil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Obstruction:

Obstruction (469 drugs)

Browse all the conditions that are associated with Obstruction:

Obstruction (647 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on atropine sulfate; diphenoxylate hydrochloride (the active ingredients of Lomotil) and Lomotil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.